Layoffs
Follow along as BioSpace tracks job cuts and restructuring initiatives.
After the FDA delayed a decision for Agios Pharmaceuticals’ sickle cell disease candidate, the biopharma is letting go of more than 35% of its R&D employees.
Biotech and pharma professionals share job hunt challenges after being let go, while a recruiting expert discusses why hiring managers prefer candidates without employment gaps and how to address gaps in interviews.
As companies invest billions of dollars to reshore manufacturing, 10 biotech and pharma businesses are reportedly trimming staff at manufacturing locations in 2026 or the coming years, with BioNTech having the deepest cuts.
Kaye/Bassman’s Michael Pietrack explores the guilt and grief executives feel when their direct reports are downsized and provides a strategy that helps both the leader and the people who need new jobs.
Three former employees of large pharmas, including Novo and Sanofi, share how they were let go. While they appreciated some aspects of their experiences, such as severance and outplacement resources, they criticized a lack of public transparency, a mishandled notification and puzzling outsourcing.
Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include dissolution and liquidation.
A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.
In this bonus episode, BioSpace Vice President of Marketing Chantal Dresner and Angela Gabriel, content manager, life sciences careers, discuss how the job market shaped up in Q3 and what Q4 might hold.
EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.
PRESS RELEASES
